文献速递类风湿关节炎

在「JAK-pot」协作的19个注册登记中评估肿瘤坏死因子抑制剂、阿巴西普、白细胞介素6抑制剂和JAK抑制剂在31846例类风湿关节炎患者中的有效性

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
PubMed 文献 · Ann Rheum Dis · 2022-06-15

该观察性队列研究纳入19个注册登记中31846例类风湿关节炎患者的治疗疗程,比较肿瘤坏死因子抑制剂、阿巴西普、白细胞介素6抑制剂和JAK抑制剂启动后1年的停药情况和CDAI应答率。调整分析显示总体停药率各组相似,JAK抑制剂和白细胞介素6抑制剂较肿瘤坏死因子抑制剂因无效停药更少、因不良事件停药更多,1年CDAI应答率在肿瘤坏死因子抑制剂、JAK抑制剂和白细胞介素6抑制剂间相似,阿巴西普略低。

要点

  • 调整后总体停药率在各治疗间相似,停药主要原因均为无效。
  • JAK抑制剂较肿瘤坏死因子抑制剂因无效停药更少(aHR 0.75,95%CI 0.67至0.83),因不良事件停药更多(aHR 1.16,95%CI 1.03至1.33)。
  • 1年CDAI应答率在肿瘤坏死因子抑制剂、JAK抑制剂和白细胞介素6抑制剂间相似,阿巴西普略低。

核心结论

  • JAK抑制剂和白细胞介素6抑制剂的调整后总体停药率和1年应答率与肿瘤坏死因子抑制剂相似。
  • 与肿瘤坏死因子抑制剂相比,JAK抑制剂因不良事件停药更多、因无效停药更少,白细胞介素6抑制剂亦如此。

研究设计与样本

  • 该研究为观察性队列研究,纳入19个注册登记中启动肿瘤坏死因子抑制剂、白细胞介素6抑制剂、阿巴西普或JAK抑制剂的类风湿关节炎患者。
  • 共纳入31846个治疗疗程:肿瘤坏死因子抑制剂17522个、阿巴西普2775个、白细胞介素6抑制剂3863个、JAK抑制剂7686个。
  • 比较各治疗1年时的停药情况和临床疾病活动指数(CDAI)应答率,分析对患者、疾病和治疗特征(包括治疗线数)进行调整并考虑竞争风险。

主要发现

  • 调整后总体停药率在所有治疗间相似,停止治疗的主要单一原因均为无效。
  • 与肿瘤坏死因子抑制剂相比,JAK抑制剂因无效停药更少(aHR 0.75,95%CI 0.67至0.83),白细胞介素6抑制剂因无效停药也更少(aHR 0.76,95%CI 0.67至0.85)。
  • 与肿瘤坏死因子抑制剂相比,JAK抑制剂因不良事件停药更多(aHR 1.16,95%CI 1.03至1.33)。
  • 调整后1年CDAI应答率在肿瘤坏死因子抑制剂、JAK抑制剂和白细胞介素6抑制剂之间相似,阿巴西普略低。

关键数值与推荐

  • JAK抑制剂因无效停药的调整风险比(aHR)为0.75(95%CI 0.67至0.83),对照为肿瘤坏死因子抑制剂。
  • 白细胞介素6抑制剂因无效停药的aHR为0.76(95%CI 0.67至0.85),对照为肿瘤坏死因子抑制剂。
  • JAK抑制剂因不良事件停药的aHR为1.16(95%CI 1.03至1.33),对照为肿瘤坏死因子抑制剂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since JAKi approval, in an international collaboration of 19 registers. METHODS: In this observational cohort study, patients initiating tumour necrosis factor inhibitors (TNFi), interleukin-6 inhibitors (IL-6i), abatacept (ABA) or JAKi were included. We compared the effectiveness of these treatments in terms of drug discontinuation and Clinical Disease Activity Index (CDAI) response rates at 1 year. Analyses were adjusted for patient, disease and treatment characteristics, including lines of therapy and accounted for competing risk. RESULTS: We included 31 846 treatment courses: 17 522 TNFi, 2775 ABA, 3863 IL-6i and 7686 JAKi. Adjusted analyses of overall discontinuation were similar across all treatments. The main single reason of stopping treatment was ineffectiveness. Compared with TNFi, JAKi were less often discontinued for ineffectiveness (adjusted HR (aHR) 0.75, 95% CI 0.67 to 0.83), as was IL-6i (aHR 0.76, 95% CI 0.67 to 0.85) and more often for adverse events (aHR 1.16, 95% CI 1.03 to 1.33). Adjusted CDAI response rates at 1 year were similar between TNFi, JAKi and IL-6i and slightly lower for ABA. CONCLUSION: The adjusted overall drug discontinuation and 1 year response rates of JAKi and IL-6i were similar to those observed with TNFi. Compared with TNFi, JAKi were more often discontinued for adverse events and less for ineffectiveness, as were IL-6i.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration. Ann Rheum Dis. 2022. PMID: 35705376. doi:10.1136/annrheumdis-2022-222586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。